NCT04170023: A trial that was reported late by Alexion Pharmaceuticals, Inc.
This trial has reported, although it was 45 days late in doing so.
Full data
| Full entry on ClinicalTrials.gov | NCT04170023 |
|---|---|
| Title | A Phase 2 Open-Label Proof of Concept Study to Assess the Efficacy, Safety, and Pharmacokinetics of the Oral Factor D (FD) Inhibitor ALXN2050 (ACH-0145228) in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients as Monotherapy |
| Results Status | Reported (late) |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 16, 2019 |
| Completion date | April 27, 2023 |
| Required reporting date | April 26, 2024, midnight |
| Actual reporting date | June 11, 2024 |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 45 |